Thomas Thum
 | The topic of this article may not meet Wikitia's general notability guideline. |
Thomas Thum | |
|---|---|
| Born | 16 November 1974 (age 49) Hildesheim, Germany |
| Alma mater | Hannover Medical School |
| Awards | Julian-Desmond Award 2022 Paul-Martini Award 2021 |
| Scientific career | |
| Fields | Medicine, Cardiology |
| Institutions | Hannover Medical School Imperial College London |
Thomas Thum (born 16 November 1974) is a German professor, cardiologist, and entrepreneur. He attended Gymnasium Josephinum in Hildesheim. Thum completed his medical studies at Hannover Medical School between 1994 and 2001, where he also achieved his medical doctorate in 2001. He then pursued further education by obtaining a PhD from the National Heart and Lung Institute at Imperial College London. This was under the supervision of Prof. Philip A. Poole-Wilson.[1]
Entrepreneurial Ventures
In 2016, Thum founded Cardior Pharmaceuticals GmbH, a biotechnology company focused on noncoding RNA-based therapeutics for heart failure.[2] Under his leadership as Managing Director, Chief Scientific (CSO) and later Chief Medical Officer (CMO), Cardior raised about €80 million through multiple financing rounds. In May 2024, Novo Nordisk acquired Cardior Pharmaceuticals in a deal valued at up to €1.025 billion.[3]
Research Contributions and Innovations
Thum worked on oligonucleotide-based therapies for heart and pulmonary diseases, particularly in targeting microRNA-21 to combat fibrosis. Moreover, his team identified the miRNA-212/132 cluster, which plays a key role in cardiac remodeling and autophagy. He led the first clinical study testing an oligonucleotide inhibitor for heart failure. This work laid the foundation for the ongoing clinical phase 2 "HF-REVERT" trial, evaluating the therapy in post-myocardial infarction patients.[4]
Awards and Recognition
References
- ↑ "Thomas Thum". profiles.imperial.ac.uk. Retrieved 2024-11-07.
- ↑ "Our Core". Cardior. Retrieved 2024-11-06.
- ↑ "News Details". Novo Nordisk. Retrieved 2024-11-06.
- ↑ Thum, Thomas; Gross, Carina; Fiedler, Jan; Fischer, Thomas; Kissler, Stephan; Bussen, Markus; Galuppo, Paolo; Just, Steffen; Rottbauer, Wolfgang; Frantz, Stefan; Castoldi, Mirco; Soutschek, Jürgen; Koteliansky, Victor; Rosenwald, Andreas; Basson, M. Albert (2008-12-18). "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts". Nature. 456 (7224): 980–984. Bibcode:2008Natur.456..980T. doi:10.1038/nature07511. ISSN 1476-4687. PMID 19043405.
- ↑ "Paul-Martini-Preis 2021". www.paul-martini-stiftung.de. Retrieved 2024-11-06.
- ↑ "Presentation of the best paper published in the EHJ in 2021". esc365.escardio.org. Retrieved 2024-11-06.
- ↑ "ERC Advanced Grant for Prof. Thomas Thum". train-heart.eu (in Nederlands). Retrieved 2024-11-06.
External links
This article "Thomas Thum" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.